Beginning to see the light

Sep 29, 2008
Molecular mechanisms of vision
Molecular mechanisms of vision

(PhysOrg.com) -- Scientists have detailed the active form of a protein which they hope will enhance our understanding of the molecular mechanisms of vision, and advance drug design.

Writing in the journal Nature, the team, including Dr Norbert Krauss from Queen Mary’s School of Biological and Chemical Sciences, has detailed the active structure of a G-protein coupled receptor for the first time.

G-protein coupled receptors are found in the cell membranes of many different animals, and are involved in sensing light and a range of chemical signals including hormones, odours, pheromones and flavours. A huge variety of therapeutic drugs, such as alpha and beta blockers, antihistamines, dopamine agonists and opioids, work by regulating the behaviour of these receptors, and any information about their structure, particularly in an active form, is of valuable use to the pharmaceutical industry.

The team, lead by academics from the Charité (Medical School of Berlin) in Germany and Chonbuk National University in South Korea, studied a G-protein coupled receptor protein called Opsin, which is found in the rod cells of our eyes.

Opsin is the first link in a chain of chemical reactions which allow us to process images and see. First it joins together with another molecule called retinal, forming a protein called Rhodopsin. This in turn reacts with particles of light called photons to join with another protein, the G-protein and stimulate vision.

The team used a technique called X-ray crystallography to analyse the structure of Opsin when it was joined together with the G-protein. They found that Opsin had adopted an active structure, significantly different from its normal inactive state. This explains why Opsin can only bond with the G-protein in its active form, and provides a picture about how Rhodopsin is activated by light, like a mechanical switch.

Dr Krauss explains: “Our findings contribute to our understanding of the primary processes underlying vision. They might also help to model the interactions of other pairs of G-protein coupled receptors and G-proteins. As Rhodopsin/Opsin is now the first example of a G-protein coupled receptor where structures of both the active and inactive forms are known, it might also serve as a model system for selectively designing therapeutic drugs which function as agonists or antagonists of G-protein coupled receptor activity.”

Citation: 'Crystal structure of opsin in its G-protein-interacting conformation' by Patrick Scheerer, Jung Hee Park et al. will be published in the journal Nature on Thursday, 25th September.

Provided by Queen Mary, University of London

Explore further: Recombinant peptide for transplantation of pancreatic islets in mice models of diabetes

add to favorites email to friend print save as pdf

Related Stories

Dairy farms asked to consider breeding no-horn cows

3 hours ago

Food manufacturers and restaurants are taking the dairy industry by the horns on an animal welfare issue that's long bothered activists but is little known to consumers: the painful removal of budding horn ...

DARPA seeks new positioning, navigation, timing solutions

9 hours ago

The Defense Advanced Research Projects Agency (DARPA), writing about GPS, said: "The military relies heavily on the Global Positioning System (GPS) for positioning, navigation, and timing (PNT), but GPS access is easily blocked by methods such as jamming. In addition, many environments in which our mil ...

Recommended for you

Novel nanoparticle therapy promotes wound healing

Mar 26, 2015

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.